FDA approves $2.125 million gene therapy from novartis Unlisted Video

Reuters reports that the Swiss drugmaker Novartis has secured U.S. approval for its gene therapy "Zolgensma". The therapy is used to treat spinal muscular atrophy (SMA). which is the leading genetic cause of death in infants. The U.S. Food and Drug Administration approved Zolgensma for pediatric patients under age 2 with SMA, including those not yet showing symptoms. The drugmaker has reportedly priced the one-time treatment at a record $2.125 million.